The Priority Review

Tag

Analysis

1 story

  1. Approvals

    Five of 10 October FDA approvals were new uses for cancer drugs the FDA had approved before

    Five of the 10 FDA approvals dated October 1 to 20, 2026 added a use to a cancer drug the agency had approved before. One, dostarlimab in rectal cancer, is an accelerated approval with a confirmatory trial requirement projected to finish by July 31, 2030.

    By Nick Bostic, Editor